Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human papillomavirus type 33 (HPV33)
- Target
- HPV33
- Molecular classification
- Double-stranded DNA virus, Papillomaviridae family, Alphapapillomavirus genus, Alpha-9 species group
01
Overview
Human papillomavirus type 33 (HPV33) is a double-stranded DNA virus classified in the alpha-9 species group of the Alphapapillomavirus genus. It infects epithelial cells, can disrupt cell cycle control via its E6 and E7 proteins, and is considered a high-risk oncogenic type associated with cervical and other anogenital cancers. HPV33 genetics show multiple lineages and sublineages (A, B, and C; with A1, A2, and A3 sublineages in lineage A), with evidence that different sublineages may confer different cancer risks. Detection of HPV33 DNA is a biomarker in clinical settings for cancer screening. Preventive vaccines provide immunity against HPV33, but there are currently no approved direct antiviral drugs for HPV33 infection.
- Other names
- Human papilloma virus type 33HPV-33HPV 33
02
Mechanism of action
Vaccines act by inducing neutralizing antibodies against viral capsid proteins (L1 protein), preventing infection. Research into antivirals or immunotherapeutics may target viral proteins (E6, E7) to restore cell cycle control or induce apoptosis in infected cells.
03
Biological functions
Infection of epithelial cellsdisruption of cell cycle regulationinhibition of apoptosisviral replicationcarcinogenesis
04
Disease associations
CancerInfection
05
Safety considerations
No notable safety concerns are associated directly with the virus itself as a therapeutic targetIncomplete vaccine coverage (not all HPV types are covered by vaccines)The virus's ability to evade immune detectionIts role in persistent infection leading to cancer
06
Interacting drugs
Prophylactic HPV vaccines containing L1 proteins from multiple HPV types (the 9-valent vaccine includes HPV33)
07
Biomarkers
HPV DNA (specifically for type 33) in clinical samples is used as a biomarker for cervical cancer risk and patient selection in diagnostic screening
Beyond the preview
Go deeper on Human papillomavirus type 33 (HPV33).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human papillomavirus type 33 (HPV33).